Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Net Margin (2019 - 2025)

Keros Therapeutics' Net Margin history spans 6 years, with the latest figure at 4066.03% for Q4 2025.

  • For Q4 2025, Net Margin fell 1312627.0% year-over-year to 4066.03%; the TTM value through Dec 2025 reached 35.62%, down 15609188.0%, while the annual FY2025 figure was 35.65%, N/A changed from the prior year.
  • Net Margin reached 4066.03% in Q4 2025 per KROS's latest filing, down from 51.04% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1588500.0% in Q1 2021 to a low of 493000.0% in Q3 2023.
  • Average Net Margin over 5 years is 86896.58%, with a median of 151.66% recorded in 2022.
  • Peak YoY movement for Net Margin: crashed -158863437bps in 2022, then skyrocketed 47935155bps in 2024.
  • A 5-year view of Net Margin shows it stood at 38.77% in 2021, then tumbled by -247bps to 134.37% in 2022, then crashed by -20844bps to 28141.96% in 2023, then soared by 132bps to 9060.24% in 2024, then plummeted by -145bps to 4066.03% in 2025.
  • Per Business Quant, the three most recent readings for KROS's Net Margin are 4066.03% (Q4 2025), 51.04% (Q3 2025), and 168.96% (Q2 2025).